Discover and read the best of Twitter Threads about #oncologists
Most recents (3)
And the road to @MICCAI_Society @MiccaiS #Singapore has started! Cannot wait to present #ImagineQuant @YaleRadiology #BrainLesWorkshop 20 hrs travel totally worth it 😅😎❤️ to learn from the best #MICCAI22. @ujjwalbaid0408 @SpyridonBakas 
#BrainLesWorkshop @MICCAI_Society @MiccaiStudents @WomenInMICCAI #ClinicalTranslation of #ML, #PACS based ML, #Neuroradiology, #GBM, Asking questions that address #radiologists & #oncologists real clinical needs! 🎊🦄🎉 #Industry #Collab @MingDeLin1234 brainlesion-workshop.org
Goodbye #Newark #NYC, looking forward to #Tokyo in 12 hrs! Dreams do come true!!! #academiclife #neurorad Thinking of @hsairmd @sairaallapeikko @theASFNR #Maui just about now! Will have to finish that episode 13 soon! @MICCAI_Society @MiccaiStudents @WomenInMICCAI #ImagineQuant
"I was diagnosed with cancer. So I took ayurvedic immunotherapy. I was feeling well but the tumors in my lungs were growing" says a 25yr old female patient , with metastatic lung carcinoma with a poor prognosis. What is Ayurvedic immunotherapy? 😡(1) #ayurveda
At the time of diagnosis , had this girl followed the accepted , approved and effective treatment , the intent would have been curative not palliative as it is now. (2)
Is there a regulatory body in India that looks into such falsely claimed cures? How many more lives will be left at the mercy of these unverified treatment methods. (3) #oncologists #cancer #alternative #medicine
Easing 'compassionate use' access to investigational drugs has been a major priority for the @FDAOncology @SGottliebFDA @tmprowell @BlumenthalG - now in @JAMAOnc our analysis of outcomes from this mechanism over 5 years @sloan_kettering ja.ma/2Ej78li [1/5]
Key findings: 208 applications IRB-approved (185 administered), 43 cancer types treated, 66 unique products. ORR 20.1% (95% CI, 14.2%-27.2%). PFS at 1-year 24.5% (95% CI, 18.2%-31.4%). Meaningful benefit - albeit in minority of patients. [2/5]
At the time of use, products were in Phase 1 (19%), Phase 2 (36%), and Phase 3 (39%) development. Children 34% of use (drug access remains major peds issue!) - no unique safety signals. Applications citing genomic rationale not associated with improved outcome @JackWestMD [3/5]
